Literature DB >> 17892849

Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.

Steven G Deeks1, Bruce D Walker.   

Abstract

Chronic viral infections can appear in two very different forms: those that are typically immunologically contained after acute symptomatic infection, such as Epstein-Barr virus (EBV), and those that predictably lead to persistent viremia and progressive clinical disease. Human immunodeficiency virus (HIV) infection is typical of the latter and has resulted in more than 20 million deaths worldwide. Here we review a remarkable subset of persons infected with HIV who are able to achieve long-term control of viremia and avoid immunodeficiency without the need for antiviral therapy. We review the contributing role of host genetic factors, innate and adaptive immune responses, and viral factors that may contribute to this phenotype. These individuals indicate that as with other potentially pathogenic chronic viral infections, the human immune system is able to fully control HIV and prevent HIV-associated disease, at least in some individuals. Further understanding of the mechanisms whereby this occurs should yield critical insights for prophylactic and therapeutic antiviral interventions.

Entities:  

Mesh:

Year:  2007        PMID: 17892849     DOI: 10.1016/j.immuni.2007.08.010

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  366 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.

Authors:  Olusimidele T Akinsiku; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

3.  Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions.

Authors:  Connie J Kim; Colin Kovacs; Tae-Wook Chun; Gabor Kandel; Brendan J W Osborne; Sanja Huibner; Kamnoosh Shahabi; Feng-Yun Yue; Erika Benko; Mario Ostowski; Rupert Kaul
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

Review 4.  Natural SIV hosts: showing AIDS the door.

Authors:  Ann Chahroudi; Steven E Bosinger; Thomas H Vanderford; Mirko Paiardini; Guido Silvestri
Journal:  Science       Date:  2012-03-09       Impact factor: 47.728

5.  Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replication.

Authors:  Stephanie A Freel; Ralph A Picking; Guido Ferrari; Haitao Ding; Christina Ochsenbauer; John C Kappes; Jennifer L Kirchherr; Kelly A Soderberg; Kent J Weinhold; Coleen K Cunningham; Thomas N Denny; John A Crump; Myron S Cohen; Andrew J McMichael; Barton F Haynes; Georgia D Tomaras
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

6.  Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses.

Authors:  Zaza M Ndhlovu; Jacqueline Proudfoot; Kevin Cesa; Donna Marie Alvino; Ashley McMullen; Seanna Vine; Eleni Stampouloglou; Alicja Piechocka-Trocha; Bruce D Walker; Florencia Pereyra
Journal:  J Virol       Date:  2012-04-18       Impact factor: 5.103

7.  Rapid, efficient functional characterization and recovery of HIV-specific human CD8+ T cells using microengraving.

Authors:  Navin Varadarajan; Douglas S Kwon; Kenneth M Law; Adebola O Ogunniyi; Melis N Anahtar; James M Richter; Bruce D Walker; J Christopher Love
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

8.  HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.

Authors:  Alan Landay; Elizabeth T Golub; Seema Desai; Jinbing Zhang; Val Winkelman; Kathryn Anastos; Helen Durkin; Mary Young; Maria C Villacres; Ruth M Greenblatt; Philip J Norris; Michael P Busch
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

9.  TLR3 activation efficiency by high or low molecular mass poly I:C.

Authors:  Yu Zhou; Ming Guo; Xu Wang; Jielang Li; Yizhong Wang; Li Ye; Ming Dai; Li Zhou; Yuri Persidsky; Wenzhe Ho
Journal:  Innate Immun       Date:  2012-10-03       Impact factor: 2.680

10.  Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.

Authors:  Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.